Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia

Abstract

Shigella sonnei and Salmonella enterica serotype Typhimurium isolates producing CTX-M b-lactamases as causes of community-acquired infection in France. Clin Infect Dis 2005; 40: 1069-70. 5. Jacoby GA, Han P. Detection of extended-spectrum b-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli.

Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy

“…The reported incidence of linezolid-induced thrombocytopenia varies, ranging from 7.5 to 48% according to the definition of thrombocytopenia [13][14][15][16][17]. Birmingham et al [17] reported that thrombocytopenia occurred in 7.5% of patients, with the mean time to 50% reduction of the platelet count being 2-3 weeks.…”

Chronic liver disease increases the risk of linezolid-related thrombocytopenia in methicillin-resistant Staphylococcus aureus-infected patients after digestive surgery

“…In a prospective study in patients receiving short-course linezolid therapy, Grau et al [11] found that a low pre-treatment platelet count was an independent factor associated with moderate to severe thrombocytopenia. In our study, we found no differences in the pre-treatment platelet count between the patients who developed thrombocytopenia and those who did not.…”

Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid

“…Linezolid treatment is associated with reversible thrombocytopenia, particularly when used for Ն14 days (2,(5)(6)(7). Patients with baseline platelet counts of 241 ϫ 10 9 /liter or less (8) and renal insufficiency (9) are at particular risk for linezolid-induced thrombocytopenia. In this context, implementing systematic monitoring programs (10) and predicting and minimizing the extent of platelet decline in high-risk patients is important.…”